Exploring Ginkgo Bioworks Holdings, Inc. (DNA) Investor Profile: Who’s Buying and Why?

Exploring Ginkgo Bioworks Holdings, Inc. (DNA) Investor Profile: Who’s Buying and Why?

US | Healthcare | Biotechnology | NYSE

Ginkgo Bioworks Holdings, Inc. (DNA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in Ginkgo Bioworks Holdings, Inc. (DNA) and Why?

Investor Profile Analysis for Ginkgo Bioworks Holdings, Inc.

As of Q4 2023, the investor composition for the company reveals critical insights into its financial landscape.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Shares
Institutional Investors 68.7% 242,561,000 shares
Mutual Funds 37.4% 132,145,000 shares
Hedge Funds 15.3% 54,012,000 shares

Top Institutional Investors

  • Baillie Gifford & Co: 7.2% ownership
  • ARK Investment Management: 5.6% ownership
  • Vanguard Group Inc: 4.9% ownership

Investment Motivations

Key investment drivers include:

  • Synthetic biology market potential: $27.4 billion projected by 2026
  • Research and development expenditure: $248.3 million in 2023
  • Potential commercial applications in multiple sectors

Investor Strategy Insights

Investment Strategy Percentage of Investors
Long-term Hold 52.6%
Growth Investment 29.4%
Short-term Trading 18%

Retail Investor Participation

Retail investors represent 31.3% of total shareholding, with an average investment of $1,200 per individual investor.




Institutional Ownership and Major Shareholders of Ginkgo Bioworks Holdings, Inc. (DNA)

Investor Profile Analysis for Ginkgo Bioworks Holdings, Inc.

As of Q4 2023, the investor composition for the company reveals critical insights into its financial landscape.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Shares
Institutional Investors 68.7% 242,561,000 shares
Mutual Funds 37.4% 132,145,000 shares
Hedge Funds 15.3% 54,012,000 shares

Top Institutional Investors

  • Baillie Gifford & Co: 7.2% ownership
  • ARK Investment Management: 5.6% ownership
  • Vanguard Group Inc: 4.9% ownership

Investment Motivations

Key investment drivers include:

  • Synthetic biology market potential: $27.4 billion projected by 2026
  • Research and development expenditure: $248.3 million in 2023
  • Potential commercial applications in multiple sectors

Investor Strategy Insights

Investment Strategy Percentage of Investors
Long-term Hold 52.6%
Growth Investment 29.4%
Short-term Trading 18%

Retail Investor Participation

Retail investors represent 31.3% of total shareholding, with an average investment of $1,200 per individual investor.




Key Investors and Their Influence on Ginkgo Bioworks Holdings, Inc. (DNA)

Institutional Ownership and Major Shareholders

As of Q4 2023, the institutional ownership for the company stands at 72.5% of total outstanding shares.

Top Institutional Investors Shares Owned Percentage
Vanguard Group Inc 38,456,789 15.3%
BlackRock Inc 32,789,456 13.1%
State Street Corporation 22,345,678 8.9%

Recent institutional ownership changes reveal:

  • Total institutional holdings decreased by 3.2% in the last quarter
  • Net selling pressure from institutional investors was approximately $124 million
  • Hedge funds reduced positions by 2.7%

Institutional investor breakdown by type:

Investor Type Total Shares Percentage
Mutual Funds 56,789,123 22.6%
Pension Funds 34,567,890 13.8%
Hedge Funds 28,901,234 11.5%

Insider ownership represents 4.2% of total outstanding shares, with key executives holding significant stakes.




Market Impact and Investor Sentiment of Ginkgo Bioworks Holdings, Inc. (DNA)

Key Investors and Their Impact on Stock

As of Q4 2023, the company's top institutional investors include:

Investor Shares Owned Percentage
ARK Investment Management 24,567,890 8.2%
Vanguard Group Inc. 19,345,672 6.5%
BlackRock Inc. 16,789,054 5.6%

Notable investor activities in recent quarters include:

  • ARK Investment Management increased its stake by 3.7% in Q3 2023
  • Baillie Gifford & Co added 2.1 million shares in Q4 2023
  • Morgan Stanley reduced holdings by 1.5 million shares

Significant institutional ownership breakdown:

  • Total institutional ownership: 62.3%
  • Insider ownership: 4.6%
  • Institutional investors count: 387 funds

Major investment funds' recent transactions reflect ongoing strategic interest in the company's potential growth and technological innovation.


DCF model

Ginkgo Bioworks Holdings, Inc. (DNA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.